Meeting
2023 ASCO Annual Meeting
Evolution of HER2 scores after neoadjuvant systemic therapy in breast cancer.
Authors
Esther G Chong
Loma Linda University Medical Center, Loma Linda, CA
Esther G Chong , Won Jin Jeon , Bryan Pham , Dan Ran Castillo , Akhil Mehta , Seyed Pairawan , Laura Denham , Gayathri Nagaraj
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3139)
DOI
10.1200/JCO.2023.41.16_suppl.3139
Abstract #
3139
Poster Bd #
337
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Identification of the activated form of the progesterone receptor (PR) in breast cancer (BC).
First Author: Jacques Bosq
Poster
2021 ASCO Annual Meeting
Breast cancer ER, PR, and HER2 expression variance by germline cancer predisposition genes.
First Author: Grace Wei
Poster
2021 ASCO Annual Meeting
Survival time in urban center breast cancer patients with CNS metastasis with or without visceral metastasis.
First Author: Miriam Pearl Klahr
Poster
2019 ASCO Annual Meeting
The prognostic role of progesterone receptor in patients with rapidly proliferating, hormone receptor-positive early breast cancer.
First Author: Sara Bravaccini